Efficacy and Safety of Adalimumab 40 mg Weekly Dosingin Patients with Resistant Psoriasis

Main Article Content

Meltem Turkmen
Sinan Dogan


Background: The recently updated dosing recommendation for adalimumab for psoriasis states that patients with inadequate response to adalimumab every other week (EOW) after 16 weeks may benefit from an increase in dosing frequency to 40 mg every week (EW).

Objectives: This study aims to investigatethe efficacy and safety experience of dose escalation of adalimumab to 40 mg weekly dosing patients with psoriasis with suboptimal response to 40 mg EOW dosing.

Methods: In this report 22 moderate-to-severe psoriasis patients treated with 40 mg adalimumab EW were evaluated retrospectively. Primary endpoints were safety and efficacy of treatment defined as statistically significant improvement of PASI and PGA in the 24 week of therapy.

Results: A total of 22 patients enrolled. Patients  were  under adalimumab 40 mg EOW therapy for a 16 weeks-1 year. We observed a rapid and significiant reduction of PASI and PGA scores in W4. By week 24, 95, 45% (n=21) of patients achieved ≥PASI 75, 72, 72% (n=16)  of patients     achieved ≥PASI 90 and 40, 9% of patients achieved PASI 100 response. The percentage of patients patients who achieved a PGA ‘Clear’ or ‘Almost Clear’ was 77, 27% (n=17) at W24. Dose escalation of adalimumab provided the achievement and long-term maintenance of clinical improvement in these patients. No side effects were observed during  40 mg EW adalimumab treatment.

Conclusions: Dose escalation could be a good approach for increasing efficacy in a subgroup of patients with an insufficient response to adalimumab, reducing symptoms of psoriasis.

Psoriasi, adalimumab, treatment, dose escalation

Article Details

How to Cite
Turkmen, M., & Dogan, S. (2021). Efficacy and Safety of Adalimumab 40 mg Weekly Dosingin Patients with Resistant Psoriasis. Asian Journal of Research in Dermatological Science, 4(1), 1-5. Retrieved from https://journalajrdes.com/index.php/AJRDES/article/view/30118
Original Research Article


Jacobson CC, Kimball AB. Epidemiology-psoriasis. In: Psoriasis and psoriatic arthritis (eds: Gordon KB, Ruderman em). Springer-Verlag BerlinHeidelberg, Germany. 2005;47-56.

Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature. 2007;445:866-73.

Rapp SR, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41:401-7.

Winterfield LS, Menter A, Gordon K, Gottlieb A. Psoriasis treatment: Current and emerging therapies. Ann Rheum Dis. 2005;64:87-90.

Lebwohl M. A clinician’s paradigm in the treatment of psoriasis. J Am Acad Dermatol. 2005;53:59-69.

Leonardi C, et al. Efficacy, safety and medication cost implications of adalimumab 40 mg weekly dosing in patients with psoriasis with suboptimal response to 40 mg every other week dosing: Results from an open-label study. Br J Dermatol. 2012;167(3):658-67.

Francesco Carubbi Safety and efficacy of Certolizumab Pegol in a reallife cohort of patients with Psoriasis and Psoriatic Arthritis J Dermatolog Treat. 2020;31(7): 692-697.

Menter A, et al. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol. 2008;58(1):106-15.

Gniadecki R, et al. Long-term optimization of outcomes with flexibleadalimumab dosing in patients with moderate to severeplaque psoriasis. JEADV. 2018;32: 1297–1304.

Mrowietz U, Kragballe K, Reich K, et al. Definition of treatmentgoals for moderate to severe psoriasis: A European consensus. Arch Dermatol Res. 2011;303: 1–10.

Camp NJ, Slattery ML. Classification tree analysis: A statistical toolto investigate risk factor interactions with an example for coloncancer (United States). Cancer Causes Control. 2002;13: 813–23.

Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: Doubleblind, randomized controlled trial and open-label extension study. J Am Acad Dermatol. 2006;55:598–606.

Van de Putte LB, Atkins C, Malaise M, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. AnnRheum Dis. 2004;63:508–516.

Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fullyhuman anti-tumor necrosis factor alpha monoclonal antibody, forthe treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. Arthritis Rheum. 2003; 48:35–45.

Colombel JF, Sandborn WJ, Rutgeerts P et al. Adalimumab formaintenance of clinical response and remission in patientswith Crohn’s disease: The CHARM trial. Gastroenterology. 2007;132:52–65.